Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2020; 10(13):5932-5942. doi:10.7150/thno.46691 This issue Cite

Review

Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients

Rasha Itani1, Mansour Tobaiqy2, Achraf Al Faraj1✉

1. Department of Radiologic Sciences, Faculty of Health Sciences, American University of Science and Technology (AUST), Beirut, Lebanon
2. Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia

✉ Corresponding author: Dr. Achraf Al Faraj, Department of Radiologic Sciences, Faculty of Health Sciences, American University of Science and Technology (AUST), Ashrafieh, Alfred Naccash Avenue, P.O. Box: 16-6452, Beirut, Lebanon. Tel.: +961 1 218716 More

Citation:
Itani R, Tobaiqy M, Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020; 10(13):5932-5942. doi:10.7150/thno.46691. https://www.thno.org/v10p5932.htm
Other styles

File import instruction

Abstract

Graphic abstract

On the 30th of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe.

In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells.

In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19.

Keywords: COVID-19, drug delivery systems, nanomedicine, theranostic nanoparticles

Citation styles

APA
Itani, R., Tobaiqy, M., Al Faraj, A. (2020). Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics, 10(13), 5932-5942. https://doi.org/10.7150/thno.46691.

ACS
Itani, R.; Tobaiqy, M.; Al Faraj, A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020, 10 (13), 5932-5942. DOI: 10.7150/thno.46691.

NLM
Itani R, Tobaiqy M, Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020; 10(13):5932-5942. doi:10.7150/thno.46691. https://www.thno.org/v10p5932.htm

CSE
Itani R, Tobaiqy M, Al Faraj A. 2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics. 10(13):5932-5942.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use